In vivo, the combination of iPSCs-DC injection and RT improved tumor-specific CD8+ T cell priming, increased trafficking of injected iPSCs-DCs to tumor-draining lymph nodes, promoted the formation of DC/CD8+ T cell aggregates, and enriched the tumor microenvironment (TME) with stem-like Slamf6+ TIM3− CD8+ T cells. The gene discussed is SLAMF6; the disease is neoplasm.